Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KARS1 | Q15046 | 3/20 | 0.37 |
| ▸ | PRKD1 | Q15139 | 11/20 | 0.37 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 2/20 | 0.35 |
| ▸ | GSK3B | P49841 | 2/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16754636 | 0.92 | KARS1 (0.38) | KARS1PRKD1PRKD2FAAHGSK3B | |
| SCHEMBL16754416 | 0.92 | PRKD1 (0.36) | KARS1PRKD1PRKD2FAAHGSK3B | |
| SCHEMBL16754300 | 0.92 | PRKD1 (0.39) | KARS1PRKD1PRKD2FAAHGSK3B | |
| SCHEMBL17778385 | 0.91 | WNT3A (0.40) | KARS1PRKD1PRKD2 | |
| SCHEMBL16238798 | 0.91 | WNT3A (0.40) | KARS1PRKD1PRKD2 | |
| SCHEMBL16754278 | 0.91 | WNT3A (0.40) | KARS1PRKD1PRKD2 | |
| SCHEMBL16754666 | 0.89 | KARS1 (0.37) | KARS1PRKD1PRKD2FAAHGSK3B | |
| SCHEMBL17618560 | 0.89 | WNT3A (0.40) | KARS1PRKD1FAAHGSK3B | |
| SCHEMBL16754451 | 0.89 | PRKD1 (0.36) | KARS1PRKD1PRKD2FAAHGSK3B | |
| SCHEMBL16754621 | 0.89 | PRKD1 (0.37) | KARS1PRKD1PRKD2FAAHGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | KARS1 1760/4885PRKD1 2346/4885PRKD2 1825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.